FDA Issues Early Alert on Medline Convenience Kits Containing Recalled BD ChloraPrep Applicators (August 17, 2026)

Key Takeaways

• On August 17, 2026, FDA CDRH issued an early alert warning that certain Medline convenience kits containing recalled BD ChloraPrep applicators present a risk of Aspergillus penicillioides contamination, and that affected products must be quarantined and destroyed.
• Affected items and lots include item number 930480, lot 4032183 (ChloraPrep Clear 1 mL single sterile applicator) and item number 930299, lot 4073005 (FREPP Clear 1.5 mL paper-covered applicator).
• The required action has been upgraded: instead of labelling affected kits so that users remove the affected component before use, customers must now destroy the entire convenience kit.
• Companies holding affected inventory should check stock, update registration and post-market surveillance processes, and confirm traceability and CAPA readiness.

Source and Applicability

• Source organisation: FDA CDRH News & Updates
• Original publication date listed by the source: August 24, 2026
• Alert date: August 17, 2026
• Source link: https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-convenience-kit-issue-medline

This article is compiled from publicly available information published by FDA CDRH News & Updates. Specific requirements are subject to the latest official publications of the relevant regulatory authorities.

Full Translation of the FDA Early Alert

CDRH Statement

CDRH is issuing this early alert to inform the public about a potentially high-risk device issue. FDA will continue to inform the public and update this page as important new information becomes available.

Affected Products

FDA is aware that Medline has sent letters to affected customers recommending that certain convenience kits affected by the recall of BD ChloraPrep applicators be removed from points of use or sale.

Affected devices: Medline convenience kits containing the following specific BD ChloraPrep products:

• ChloraPrep Clear 1 mL single sterile applicator — item number: 930480; lot number: 4032183
• FREPP Clear 1.5 mL paper-covered applicator — item number: 930299; lot number: 4073005

A complete list of affected products is available on the FDA alert page.

Actions to Be Taken

Check inventory for convenience kits affected by this issue, quarantine them, and destroy the entire kit after completing the response form. Note that these kits were previously identified as part of a recall and may carry added labels instructing users to remove and discard the affected components at the point of use.

On August 11, Medline sent a letter to all affected customers recommending the following actions:

• Note that the action required for certain products identified in previous Medline notices has changed: because of potential contamination, customers of the products listed in this letter should destroy the entire convenience kit.
• Medline's earlier notice of June 12, 2026 required customers to apply labels to affected convenience kits indicating that the affected components should be removed and discarded before use.
• This updated action applies only to the products listed in this notice and does not affect other convenience kits covered by the June 12, 2026 notice.
• Immediately check inventory for convenience kits affected by this issue. Quarantine all affected products.
• Destroy the affected products after completing the response form.
• If you are a distributor, or have resold or transferred this product to another company or individual, communicate this recall communication to that party. Ask customers to destroy any affected product. You should record the customer's inventory quantity on the response form.

Please check this page for updates. FDA is currently reviewing information about this potentially high-risk device issue and will continue to inform the public as important new information becomes available.

Reason for the Alert

Medline stated that certain convenience kits containing recalled BD ChloraPrep applicators should be taken out of use because, under certain environmental conditions, fungal contamination may occur, resulting in the growth of Aspergillus penicillioides.

This action applies to products previously identified in Medline's June 12 notice. Note that, based on additional recall details provided by BD (Becton, Dickinson and Company) regarding its ChloraPrep applicators, the action required for certain lots in the original notice has changed. Following the initial notice, BD provided additional information regarding its recall of the ChloraPrep Clear 1 mL single sterile applicator, item number 930480, lot number 4032183, and the FREPP Clear 1.5 mL paper-covered applicator, item number 930299, lot number 4073005.

Contamination of skin preparation products with Aspergillus penicillioides may lead to serious adverse health consequences, including systemic infection, sepsis, illness and death. If the fungus enters the patient's bloodstream during placement of an intravascular catheter, the catheter would likely need to be removed, requiring an additional procedure. Surgical site infections may also require medical and surgical intervention, as well as long-term antifungal therapy.

As of August 17, Medline has not reported serious injuries or deaths related to this issue.

Intended Use of the Device

Convenience kits contain a variety of surgical instruments, dressings and/or other materials, as well as drug components intended for use in various surgical procedures.

Contact Information

Customers in the United States who experience adverse events, have quality concerns or have questions about this issue should contact Medline at 866-359-1704 or recalls@medline.com.

How to Report Problems

Healthcare professionals and consumers may report adverse reactions or quality problems experienced with the use of these devices to MedWatch, the FDA Safety Information and Adverse Event Reporting Program.

AIMEILI Regulatory Interpretation and Business Impact

What This Information Means for Medical Device Companies

Information of this kind, published by FDA CDRH News & Updates, should first be captured within a company's regulatory intelligence and post-market surveillance scope rather than being read only as general news. Companies need to determine whether the update is a guidance document, recall safety information, product approval, digital health item, quality system matter or post-market regulatory information, and confirm whether it affects existing registration projects or products under development.

Where the content concerns a specific product, test performance, risk communication or regulatory action, companies should further assess whether it affects product classification, the 510(k), De Novo or PMA pathway, technical documentation, labelling and instructions for use, quality system records or post-market reporting obligations. For companies pursuing U.S. market registration, the original source link, publication date, scope of application and internal conclusions should be recorded in the project file.

Documentation to Review

Companies are advised to review the basis for product classification, applicable regulatory provisions, predicate device or substantial equivalence determinations, performance testing, software and cybersecurity documentation, risk management, clinical evidence, labelling and instructions for use, and quality system readiness.

Common Risks

Common risks include misjudging the FDA pathway, overlooking changes in guidance documents, insufficiently designed performance testing, over-broad label claims, unclear post-market reporting obligations, and applying documentation prepared for other markets directly to U.S. registration.

AIMEILI's View

Although this FDA early alert directly concerns Medline convenience kits and BD ChloraPrep applicators, its regulatory signal carries cross-category warning value for Chinese medical device exporters. FDA treats the situation of a convenience kit containing a recalled component as a potentially high-risk issue and requires customers to remove the entire product from points of use and sale and destroy it, rather than merely removing the problematic component. This indicates that, in the registration and post-market management of combination products and surgical kits, regulators increasingly tend to address risk at the level of the finished kit as a whole. Chinese companies exporting surgical packs, interventional packs, puncture kits and similar combination devices should re-examine whether their own products contain components sourced from other manufacturers and whether component suppliers' recall information is captured within their own post-market surveillance procedures.

From a registration pathway perspective, if a Chinese company's convenience kit or surgical pack is already registered with FDA through the 510(k) or De Novo route, then when a third-party component contained in the product (such as an antiseptic applicator, puncture needle or catheter) is changed or recalled, the company cannot simply wait for the component manufacturer to handle the matter; it should assess on its own whether a new 510(k) submission or an amendment to registration documents is required. If a component poses a contamination risk, updates to performance verification documentation such as sterility assurance, biocompatibility and microbial limits may also be involved. Companies should establish a component supplier list and a change management process to ensure that supplier recall information is promptly reflected in their own technical documentation.

From a quality system perspective, the FDA early alert requires distributors and healthcare facilities to complete response forms and quarantine and destroy products, which in substance triggers corrective and preventive action under the 21 CFR Part 820 / CAPA system. Chinese manufacturers should review their supplier audits, incoming inspection, nonconforming product control and product traceability systems to confirm whether they can identify the distribution of affected lot numbers within 24 hours. If FDA subsequently escalates the early alert into a formal recall, companies will also need to cooperate by submitting recall reports and corrective action reports and by completing customer notifications within the timeframes specified by FDA. Regarding labelling and instructions for use, the original notice required added labels instructing users to remove the component before use, whereas the update now requires destruction of the entire kit. This shows that product labelling or additional labelling cannot eliminate the contamination risk; companies should avoid mitigating risk solely through label changes and should instead assess whether warnings and contraindications in the instructions for use need to be updated.

For Chinese companies that have established a U.S. agent or distributor, this event also highlights the need for particular attention to adverse event reporting obligations. FDA asks healthcare professionals and consumers to report problems through MedWatch, but manufacturers also bear MDR reporting responsibilities under 21 CFR Part 803. Once an infection related to fungal contamination occurs, the company should assess within the specified timeframe whether the event constitutes death, serious injury or an event requiring corrective action, and submit a report to FDA in a timely manner. Chinese exporters are advised to specify supply chain notification obligations in quality agreements with distributors, ensuring that FDA alerts, supplier recalls and customer complaints reach the registration holder and manufacturer without delay. At the same time, device identifier information in the UDI database (AccessGUDID) should be kept up to date so that affected products and lot numbers can be identified quickly in similar events, improving the efficiency of post-market response.

FAQ

Does an update to an FDA public page necessarily represent a regulatory change?

No. An update to a public FDA page does not automatically constitute a regulatory change. Companies need to distinguish between news items, guidance documents, database pages, recall information and formal regulatory documents, and important content should be verified against the original FDA publication and the applicable regulations before any compliance decision is made.

What should companies do after seeing an FDA update?

Companies should first determine whether the update affects product classification, the registration pathway, technical documentation or post-market obligations, and then decide whether the project plan needs to be updated. Where the update concerns products already on the U.S. market or under registration review, the original source link, publication date, applicability and internal assessment conclusions should be recorded in the project file, and affected inventory or documentation should be reviewed accordingly.

Editorial Review and Scope of Application

• Content author: AIMEILI Regulatory Editorial Team
• Professional review: AIMEILI Medical Device International Registration Project Team
• Source principles: Priority is given to official regulatory authorities, international organisations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.
• Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the regulatory authority of the target country, testing conclusions or legal opinions.

Related Reading

• March 18, 2020 — Health Canada issues notice on expedited review of COVID-19 health product submissions
• July 22, 2026 — FDA announces participants selected for the TEMPO digital health device pilot
• August 12, 2025 — FDA issues early warning on CooperSurgical ventilator issue
• August 24, 2026 — Health Canada issues notice on changes to the medical device Special Access Program application process
• August 19, 2026 — FDA approves Aletta, the first stand-alone robotic blood collection device
• April 3, 2025 — FDA issues discussion paper on regulatory considerations for generative AI-enabled medical devices and requests comments

Contact AIMEILI

Need to assess your registration pathway? Please provide the product name, intended use, target countries and the existing documentation base, and AIMEILI can help assess the registration pathway, documentation gaps and compliance risks.